CONSIDER USING CBD WHEN TAKING NEUROTOXIC CHEMOTHERAPY OR OTHER DRUGS: GreenBridge Medical: Family Medicine Physicians

If you have any doubts with regard to the efficacy of CBD for treatment of neuropathic pain, please enjoy the references, a lot of references, at the bottom of this blog. I mostly chose references where whole plant CBD rich extracts were being used, as this is what we have in our medical cannabis medicine cabinet.

So, if we agree that CBD is a safe way to often ameliorate the pain of drug induced, and other neuropathic pain, AND we note that CBD is clearly neuro-protective, why not give it in low dose to patients who are taking any potential neurotoxic medication. It clearly cannot hurt and doing this in a study form would/could/should be pretty easy.

There are millions of patients in the US taking drugs with potential neuro-toxicity. The cost in pain and dollars is immense. I often see cancer patients in remission from their cancer for years, but are nearly fully debilitated from neuropathic pain. They often can’t feel the bottom of their feet, so they can’t drive and have difficulty with walking. The pain itself, can be “suicidal level” pain.

Anyone interested in starting an informal study for a few years and see what happens?

ARTICLES FROM GW PHARMA:(They use “Sativex” which is a whole plant 1:1 CBD:THC extract

GWPharma – New Published Study Shows Sativex® Successfully Treats Neuropathic PainRelevance: 904

New Published Study Shows Sativex® Successfully Treats Neuropathic Pain New Published Study Shows Sativex® Successfully Treats Neuropathic Pain New Published Study Shows Sativex® Successfully Treats Neuropathic Pain 12 November 2007 GW Pharmaceuticals plc (AIM: GWP) today announces that The I…

GWPharma – Results of Sativex® Phase III Neuropathic Pain Trials Demonstrate Benefits for High Need Treatment-Resistant PatientsRelevance: 902

Results of Sativex® Phase III Neuropathic Pain Trials Demonstrate Benefits for High Need Treatment-Resistant Patients Results of Sativex® Phase III Neuropathic Pain Trials Demonstrate Benefits for High Need Treatment-Resistant Patients Results of Sativex® Phase III Neuropathic Pain Trials Demonst…

GWPharma – Neuropathic PainRelevance: 902

Cancer Pain Neuropathic Pain Other Mechanism of Action Home Sativex Sativex R Therapeutic Uses NeuropathicPainNeuropathic Pain Neuropathic pain is a chronic, debilitating and widespread condition with an estimated prevalence of one per cent of the general population. Neuropathic pain ar…

GWPharma – Start of Second Phase III Trial in MS Neuropathic PainRelevance: 887

Start of Second Phase III Trial in MS Neuropathic Pain Start of Second Phase III Trial in MS Neuropathic Pain Start of Second Phase III Trial in MS Neuropathic Pain 9 August 2006 Porton Down, UK, 9 August 2006 – GW Pharmaceuticals plc (AIM: GWP) announces the start of a second pivotal Phase I…

GWPharma – GW Announces Positive Preliminary Results with its Cannabis Medicine in Phase III Neuropathic PainTrialRelevance: 876

GW Announces Positive Preliminary Results with its Cannabis Medicine in Phase III Neuropathic Pain Trial GW Announces Positive Preliminary Results with its Cannabis Medicine in Phase III Neuropathic Pain Trial GW Announces Positive Preliminary Results with its Cannabis Medicine in Phase III Neuro…

GWPharma – Sativex® Phase III Trial in MS Neuropathic Pain Completes Patient RecruitmentRelevance: 867

Sativex® Phase III Trial in MS Neuropathic Pain Completes Patient Recruitment Sativex® Phase III Trial in MS Neuropathic PainCompletes Patient Recruitment Sativex® Phase III Trial in MS Neuropathic Pain Completes Patient Recruitment 30 August 2007 GW Pharmaceuticals plc (AIM: GWP) announces …

GWPharma – New Published Study Shows Sativex® Provides Effective Long Term Treatment of MS NeuropathicPainRelevance: 859

New Published Study Shows Sativex® Provides Effective Long Term Treatment of MS Neuropathic Pain New Published Study Shows Sativex® Provides Effective Long Term Treatment of MS Neuropathic Pain New Published Study Shows Sativex® Provides Effective Long Term Treatment of MS Neuropathic Pain 17 O…

GWPharma – Preliminary Results from Sativex® Phase III Multiple Sclerosis spasticity studyRelevance: 839

…e GW with a regulatory route in Europe for the spasticity indication, the bulk of our positive clinical data relates to neuropathic pain. We have two further Phase III neuropathic pain studies due to report later this year and we need to consider with our marketing partners the relative benefits of …

GWPharma – Sativex®, a Cannabis-Based Medicine, Significantly Reduces Central Neuropathic Pain in People with Multiple SclerosisRelevance: 831

Sativex®, a Cannabis-Based Medicine, Significantly Reduces Central Neuropathic Pain in People with Multiple Sclerosis Sativex®, a Cannabis-Based Medicine, Significantly Reduces Central Neuropathic Pain in People with Multiple Sclerosis Sativex®, a Cannabis-Based Medicine, Significantly Reduces Ce…

Author

Allan Frankel, MD